+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

High-dose therapy and autologous stem cell transplantation in Hodgkins disease patients who progress after primary chemotherapy



High-dose therapy and autologous stem cell transplantation in Hodgkins disease patients who progress after primary chemotherapy



Bone Marrow Transplantation 15(Suppl. 1): S229




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 031696964

Download citation: RISBibTeXText


Related references

Phase I Study of Involved Field Radiation Therapy Preceding High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High Risk Hodgkins Disease and Non-Hodgkins Lymphoma. Blood 100(11): Abstract No 3405, November 16, 2002

High dose therapy followed by autologous stem cell transplantation for patients with primary refractory Hodgkins disease Evaluation of prognostic factors. Blood 94(10 Suppl. 1 Part 1): 175a, Nov 15, 1999

High-dose chemotherapy followed by autologous stem cell transplantation for 99 patients with relapsed or refractory Hodgkins disease. Onkologie 18(Suppl. 2): 43, 1995

Ten-year follow-up of the first 100 patients having received high-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkins disease in Vancouver Long-term complications and causes of death. Blood 102(11): 116a, November 16, 2003

High dose therapy and autologous stem cell transplantation for adults with Hodgkins disease in first relapse after chemotherapy Conventional dose salvage therapy prior to ASCT has no effect on outcome Results from the EBMT. Blood 88(10 Suppl. 1 Part 1-2): 486A, 1996

Long-term follow-up of 100 patients undergoing high-dose chemotherapy and autologous stem cell transplantation for Hodgkins disease. Blood 90(10 Suppl. 1 Part 1): 593A, Nov 15, 1997

Thirty percent of adult patients with primary refractory Hodgkins disease are progression free at 5 years after high dose therapy and autologous stem cell transplantation Data from 290 patients reported to the EBMT. Blood 88(10 Suppl. 1 Part 1-2): 486A, 1996

Phase I clinical trial of Zevalin in patients with B-cell non-Hodgkins lymphoma with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation. Blood 102(11): 30a, November 16, 2003

Changes of immunological reconstitution after high dose chemotherapie and autologous bone marrow transplantation or peripheral stem cell transplantation in patients with Hodgkins disease or non-Hodgkins lymphoma. Annals of Hematology 73(Suppl. 2): A43, 1996

High-dose cyclophosphamide, BCNU, VP16-213 +- cisplatin and autologous stem cell transplantation for patients with Hodgkins disease who fail to enter a complete remission after combination chemotherapy. Blood 84(10 Suppl. 1): 162A, 1994

Results of high dose chemotherapy and autologous stem cell transplantation in patients with high and low grade non-Hodgkins lymphoma. Blood 98(11 Part 2): 389b, November 16, 2001

High-Dose Chemotherapy, Autologous Stem Cell Transplantation and Ex Vivo Lymphoma Cell Purging Using B-Cell High Density Microparticles Cell Separation System PCR Does Not Accurately Predict Disease Recurrence in Patients with Follicular Non-Hodgkins Lymphoma. Blood 100(11): Abstract No 3296, November 16, 2002

A phase I and pharmacokinetic study of paclitaxel incorporated into the augmented high-dose cyclophosphamide, carmustine and etoposide as conditioning chemotherapy for autologous stem cell transplantation in patients with Hodgkins and non-Hodgkins lymphoma. Blood 94(10 Suppl. 1 Part 2): 320b, Nov 15, 1999

Rituximab in patients with relapsed non Hodgkins lymphoma after autologous stem-cell transplantation with high dose chemotherapy. Acta Haematologica (Basel) 103(Suppl. 1): 56, 2000

High-dose chemotherapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasms for patients with Hodgkins lymphoma A comparison of conventional therapy alone versus conventional therapy followed by AHSCT. Blood 102(11): 116a-117a, November 16, 2003